Hyperglycosylated hCG Drives Malignancy in Most or All Human Cancers: Tying All Research Together

Abstract

Objectives: Two forms of hCG are produced, the hormone hCG binding a luteinizing hormone/hCG joint receptor and the autocrine hyperglycosylated hCG binding a TGF-ß receptor. In pregnancy, hyperglycosylated hCG drives placental cell growth and invasion in implantation of pregnancy. It also blocks apoptosis. Human cancer cells steal the hCG ß-subunit gene and use hyperglycosylated hCG and its ß-subunit to drive malignancy. Here we examine research into hyperglycosylated hCG and its ß-subunit, and show that these molecules drive malignancy in most or possibly all human cancers. Methods: Mouse monoclonal antibody B152was raised against intact hyperglycosylated hCG, batch C5. The antibody binds hyperglycosylated hCG and its ß-subunit but does not bind the hormone hCG or its subunits. Total hCG was measured using the Siemens Immulite hCG assay, hyperglycosylated hCG and its ß-subunit were measured using the antibody B152 assay. Results: Eight independent center show that the hCG ß-subunit produced by cancers promotes malignancy, enhances cancer cell growth, cancer cell invasion and blockage of apoptosis in cancers. A study of 42 choriocarcinoma cases shows that percentage hyperglycosylated hCG exactly correlates with weekly doubling rate of cancer. It is concluded that hyperglycosylated hCG drive malignancy in this cancer. In a study with 7 separate cancers it is shown that increasing concentrations of hyperglycosylated hCG enhance all cancers. Increasing concentration of monoclonal antibody B152. Hyperglycosylated hCG and its ß-subunit drives cancer growth, cancer invasion and blocks apoptosis in cancer cells. Antibody B152 suppressed cancer cell growth creating a non-malignant-like state (no growth, no invasion), with no cancer growth over a starting 70% confluency. Conclusions: Choriocarcinoma is an example of cancer driven in malignancy by hyperglycosylated hCG, cancer aggression (weekly doubling rate) exactly correlating with percent hyperglycosylated hCG. In examining cancers, antibody B152 suppresses malignancy totally halting cancer growth in 7 of 7 cancer. This confirms that only the antigens, hyperglycosylated hCG and its ß-subunit drives malignancy in cancer cases.